Page last updated: 2024-10-26

brl 42810 and Body Weight

brl 42810 has been researched along with Body Weight in 3 studies

Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.

Research Excerpts

ExcerptRelevanceReference
"A multicenter, open-label study evaluated the single-dose pharmacokinetics and safety of a pediatric oral famciclovir (prodrug of penciclovir) formulation in infants aged 1 to 12 months with suspicion or evidence of herpes simplex virus infection."5.14Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children. ( Blumer, J; Hamed, K; Kaiser, G; Rodriguez, A; Sallas, W; Sánchez, PJ, 2010)
"To develop a population pharmacokinetic model for penciclovir (famciclovir is a prodrug of penciclovir) in adults and children and suggest an appropriate dose for children."1.35Population pharmacokinetics and optimal design of paediatric studies for famciclovir. ( Aarons, L; Graham, G; Kaiser, G; Looby, M; Matthews, I; Ogungbenro, K, 2009)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Blumer, J1
Rodriguez, A1
Sánchez, PJ1
Sallas, W1
Kaiser, G2
Hamed, K1
Ogungbenro, K1
Matthews, I1
Looby, M1
Graham, G1
Aarons, L1
Thackray, AM1
Field, HJ1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter, Open-label, Single-arm Study to Evaluate the Single-dose Pharmacokinetics, Acceptability and Safety of Famciclovir Oral Pediatric Formulation in Infants 1 Month to Less Than 1 Year of Age With Herpes Simplex Virus Infections[NCT00448227]Phase 218 participants (Actual)Interventional2007-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Pharmacokinetics of Single Dose - AUC(0-6h)

Measured by AUC(0-6h) - Area under the plasma concentration time curve from time zero up to 6 hours post dose (i.e. the time of the last sample). (NCT00448227)
Timeframe: Plasma samples were collected at 0.5, 1, 4 and 6 hours after dosing.

Intervention(μg/mL)•h (Mean)
Famciclovir: Infants 1 to <3 Months2.22
Famciclovir: Infants 3 to <6 Months3.16
Famciclovir: Infants 6 to 12 Months8.77

Pharmacokinetics of Single Dose - AUC(0-tlast)

Measured by AUC(0-tlast) - Area under the plasma concentration time curve from time zero to the last quantifiable concentration-timepoint. (NCT00448227)
Timeframe: Plasma samples were collected at 0.5, 1, 4 and 6 hours after dosing.

Intervention(μg/mL)•h (Mean)
Famciclovir: Infants 1 to <3 Months2.09
Famciclovir: Infants 3 to <6 Months3.16
Famciclovir: Infants 6 to 12 Months8.68

Pharmacokinetics of Single Dose - Cmax

Measured by Cmax - The maximum plasma concentration of study medication (NCT00448227)
Timeframe: Plasma samples were collected at 0.5, 1, 4 and 6 hours after dosing.

Interventionμg/mL (Mean)
Famciclovir: Infants 1 to <3 Months0.69
Famciclovir: Infants 3 to <6 Months0.74
Famciclovir: Infants 6 to 12 Months3.24

Pharmacokinetics of Single Dose - Tmax

Measured by Tmax - The time after administration of a drug when the maximum plasma concentration is reached. (NCT00448227)
Timeframe: Plasma samples were collected at 0.5, 1, 4 and 6 hours after dosing.

Interventionhours (Median)
Famciclovir: Infants 1 to <3 Months1.00
Famciclovir: Infants 3 to <6 Months4
Famciclovir: Infants 6 to 12 Months1.02

Acceptability of the Famciclovir Pediatric Formulation as Assessed by Study Personnel

"Assessed by the study personnel using a 5-point scale after dosing:~Very badly accepted/unacceptable: infant showed great displeasure, compromising use of formulation~Badly but accepted: infant showed displeasure with dosing but could be coaxed to take complete dose~Neither good nor bad: infant showed no apparent displeasure and with little effort was coaxed to take complete dose~Well accepted: infant appeared to enjoy the formulation and with little coaxing ingested most of dose~Very well accepted: infant appeared eager and ingested most of dose without special coaxing" (NCT00448227)
Timeframe: Immediately after dosing

,,,
InterventionParticipants (Number)
Very badly / unacceptableBadly but acceptedNeither good nor badWell acceptedVery well accepted
Famciclovir: Infants 1 to <3 Months10024
Famciclovir: Infants 3 to <6 Months00203
Famciclovir: Infants 6 to 12 Months01211
Total11438

Acceptability of the Famciclovir Pediatric Formulation as Assessed by the Patient's Caregiver

"Assessed by the caregiver using a 5-point scale immediately after dosing:~Very badly accepted/unacceptable: infant showed great displeasure, compromising use of formulation~Badly but accepted: infant showed displeasure with dosing but could be coaxed to take complete dose~Neither good nor bad: infant showed no apparent displeasure and with little effort was coaxed to take complete dose~Well accepted: infant appeared to enjoy the formulation and with little coaxing ingested most of dose~Very well accepted: infant appeared eager and ingested most of dose without special coaxing" (NCT00448227)
Timeframe: Immediately after dosing

,,,
InterventionParticipants (Number)
Very badly / unacceptableBadly but acceptedNeither good nor badWell acceptedVery well accepted
Famciclovir: Infants 1 to <3 Months10024
Famciclovir: Infants 3 to <6 Months00203
Famciclovir: Infants 6 to 12 Months01121
Total11348

Tolerability of of the Famciclovir Pediatric Formulation as Assessed by Study Personnel.

"Tolerability was assessed by the study personnel 30 minutes after dosing using the following scale:~Significant emesis occurred,~Infant spit out most of the dose ingesting less than half of what was administered,~Infant spit out some of the dose, but ingested at least 50% of what was administered,~Infant was able to ingest and retain the dose administered" (NCT00448227)
Timeframe: 30 minutes after dosing

,,,
InterventionParticipants (Number)
Significant emesis occurredSpit out most of the dose, ingested less than halfSpit out some of the dose, ingested at least 50%Able to ingest and retain dose
Famciclovir: Infants 1 to <3 Months1007
Famciclovir: Infants 3 to <6 Months0005
Famciclovir: Infants 6 to 12 Months0005
Total10017

Trials

1 trial available for brl 42810 and Body Weight

ArticleYear
Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5

    Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Antiviral Agents; Body Weight; Capsules; Child; Chil

2010

Other Studies

2 other studies available for brl 42810 and Body Weight

ArticleYear
Population pharmacokinetics and optimal design of paediatric studies for famciclovir.
    British journal of clinical pharmacology, 2009, Volume: 68, Issue:4

    Topics: 2-Aminopurine; Adult; Age Factors; Antiviral Agents; Area Under Curve; Body Weight; Child; Child, Pr

2009
Famciclovir and valaciclovir differ in the prevention of herpes simplex virus type 1 latency in mice: a quantitative study.
    Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:7

    Topics: 2-Aminopurine; Acyclovir; Animals; Antiviral Agents; Body Weight; Brain; Cell Culture Techniques; De

1998